BridgeBio Pharma
Manufacturing · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 250, Palo Alto, Calif...Phone Number
(650) 391-9740Website
www.bridgebio.comRevenue
$580 MillionStock Symbol
BBIOIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About BridgeBio Pharma
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Explore more
BridgeBio Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BridgeBio Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BridgeBio Pharma has recently received funding, and reach out quickly before it becomes old news!
Click to see if BridgeBio Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at BridgeBio Pharma
Funding: Get notified immidiatlly once BridgeBio Pharma has new funding data
Check out if BridgeBio Pharma is spiking on competitors!
Earning: See what the market has to say on BridgeBio Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when BridgeBio Pharma launches new products
BridgeBio Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to BridgeBio Pharma
Compare insights from companies similar to BridgeBio Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BridgeBio Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BridgeBio Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BridgeBio Pharma.
BridgeBio Pharma financials insights
Gather financial insights about BridgeBio Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series C
$135M
2019
Other Financing Round
$299.2M
2020
Debt
$475M
2021
Debt
$750M
2025
Other Financing Round
$300M
2026
Stock/Share Issuance
$1B
BridgeBio Pharma Tech Stack
A closer look at the technologies used by BridgeBio Pharma
See more technologies
Most Recent Scoops
Hiring Plans
BridgeBio Pharma has more open roles in Information Technology than it has had at any time in the past 6 months. Technologies mentioned include: ServiceNow, DocuSign, Moveworks, and SQL. Areas of expertise include: Game Ai, Reporting Tools, Integral Calculus, Data Analysis, Requirements Traceability, Process Flow Diagrams, and Software Documentation.
Hiring Plans
Open Position
Open Position
Open Position
Person-Based
Earnings, Finance
BridgeBio Pharma News & Media
BridgeBio to Participate in September Investor Conferences
PALO ALTO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
- This voluntary agreement expands access for Medicaid patients to BridgeBio’s currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseasesAcoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
- Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline through 42 months based on CMR imaging, with up to half of patients showing clinically meaningful improvement in cardiac function in the completer analysisBridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
- The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence of amyloid regression in a subset of patients
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BridgeBio Pharma
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... Read More
